Coronary heart disease and dyslipidemia: A cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: The PRINCEPS study

Preventive Cardiology

Volumn 12, Issue 2, 2009, Pages 65-71

  de Rojas, Francisco Díaz ^a   De Frutos, Trinidad ^a   Ponte, Ana ^a   Chacón, Joaquin Mateos ^b   Vitale, Gustavo C ^b  

^a Medical Department   (Spain)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; EXERCISE; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; SPAIN;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TREATMENT OUTCOME;

EID: 64249138815     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.00022.x     Document Type: Article

References (37)

1. Smith SC, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention. A scientific statement from the World Health and Stroke Forum. Circulation. 2004;109:3112-3121.
2. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidaemia in high-risk patients: Targets still not met. Am J Med. 2006;119:676-683.
3. García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, et al. Current lpid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics. 2004;22(suppl 3):1-12.
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -Lipid Lowering Arm (ASCOT- LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
6. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
7. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA. 2004;291:1071-1080.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol. 2004;44:720-732.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
10. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990;81:1721-1733.
11. Deedwania PC. Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. Med Clin North Am. 1995;79:973-998.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
13. National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation. 2002;106:3143-3421.
14. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis. 2004;173:381-391.
15. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554-572.
16. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient. Am J Cardiol. 1997;80:45H-52H.
17. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now. Circulation. 2001;103:2768-2770.
18. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
19. Pearson TA. The undertreatment of LDL-cholesterol: Addressing the challenge. Int J Cardiol. 2000;74(suppl 1):S23-S28.
20. de Velasco JA, Cosin J, Lopez Sendon JL, et al. Secondary prevention of myocardial infarction in Spain. The PREVERSE study. [Article in Spanish]. Rev Esp Cardiol. 1997;50:406-415.
21. De Velasco JA, Cosin J, Lopez-Sendon JL, et al. New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study. [Article in Spanish]. Rev Esp Cardiol. 2002;55:801-809.
22. Fonarow GC, Watson KE. Effective strategies for long-term statin use. Am J Cardiol. 2003;92:27i-34i.
23. Banegas JR, Vegazo O, Serrano P, et al. The gap between dyslipidemia control perceived by physicians and the objective control patterns in Spain. Atherosclerosis. 2006;188:420-424.
24. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
25. Maki KC, Davidson MH, Dicklin MR. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT utilizing novel E-technology (NEPTUNE) II survery. Can J Cardiol. 2006;22:315-322.
26. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol. 2006;98:1231-1233.
27. Diamantopoulos EJ, Athyros VG, Yfanti GK, et al. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology. 2005;56:731-734.
28. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189.
29. Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA). Gender, ethnicity, and coronary artery calcium. Circulation. 2006;113:647-656.
30. Gonzalez-Juanatey JR, Alegria-Ezquerra E, Aznar-Costa J, et al. Knowledge and implementation of cardiovascular risk clinical practice guidelines by general practitioners and specialists. [Article in Spanish]. Rev Esp Cardiol. 2006;59:801-806.
31. de la Peña Fernández A, Suárez Fernández C, Cuende Melero I, et al. Integral control of risk factors in patients of high and very high cardiovascular risk in Spain. CIFARC project. [Article in Spanish]. Med Clin (Barc). 2005;124:44-49.
32. de la Peña Fernández A, Roca Villanueva B, Cuende Melero I, et al. [Effect of a global intervention in the integral control of multiple risk factors in patients at high or very high cardiovascular risk. CIFARC 2 project]. Rev Clin Esp. 2007;203:112-120.
33. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT utilizing novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556-563.
34. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80:587-595.
35. Neal RC, Jones PH. Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag. 2006;2:31-38.
36. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: Dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin. 2006;22:511-528.
37. Genest J. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Cn J Cardiol. 2006;22:863-868.